John W. LAMPE,Paul S. Watson,David J. Slade,Ward M. Peterson,Christopher S. Crean,Jason L. Vittitow,Jonathan Bryan DeCamp,Nicholas F. Pelz
申请号：
US13614641
公开号：
US20130012543A1
申请日:
2012.09.13
申请国别(地区):
US
年份:
2013
代理人:
摘要：
The present invention is directed to synthetic cytoskeletal active compounds that are inhibitors of rho-associated protein kinase. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with cytoskeletal reorganization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or Formula II, wherein said amount is effective to influence the actomyosin interactions, for example by leading to cellular relaxation and alterations in cell-substratum adhesions.
